COMP <GO>
ENOV vs LLY // EV/EBITDA & P/E VALUATION
Enovis Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ENOV 0
— LLY 11
■ METRIC PARITY
LAST: $22.81 (+4.11%) • MKT CAP: $1.32B
valuation
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENOV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENOV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.80% | 83.64% | -23.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 32.36% | -65.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.51% | 2.30% | -0.79 | LLY | /fcf-yield <GO> |
| Operating Margin | -50.00% | 40.21% | -90.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -52.70% | 31.90% | -84.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 45.51% | -38.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.29 | -9.09 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 66.6 | -18.32 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.32B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENOV REV | LLY REV | ENOV GROSS % | LLY GROSS % | ENOV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.25B | $65.18B | 59.8% | 83.0% | $19.9M | $16.81B |
| FY 2024 | $2.11B | $45.04B | 56.0% | 81.3% | -$67.2M | $8.82B |
| FY 2023 | $1.71B | $34.12B | — | 79.3% | $135.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENOV // BETA —
LLY // BETA 0.51